Topical oxybutynin antiperspirant for axillary hyperhidrosis: a phase IIb PROBE design clinical trial (TODAY trial)
Antitranspirante tópico de oxibutinina para hiperidrose axilar: um ensaio clínico de fase IIb com desenho PROBE (estudo TODAY)
Samantha Neves; Elisete Isabel Crocco; Viviane Santana da Silva; Felipe Menegueti; Alexia Paganotti; Ricardo Sanchez Boix; Nelson Wolosker; Roberto Augusto Caffaro
Abstract
Keywords
Resumo
Palavras-chave
References
1 Nawrocki S, Cha J. The etiology, diagnosis, and management of hyperhidrosis: a comprehensive review. Etiology and clinical work-up. J Am Acad Dermatol. 2019;81(3):657-66.
2 Schick CH. Pathophysiology of hyperhidrosis. Thorac Surg Clin. 2016;26(4):389-93.
3 Sammons JE, Khachemoune A. Axillary hyperhidrosis: a focused review. J Dermatolog Treat. 2017;28(7):582-90.
4 Kamikava DYF, Wolosker N, Silva M, Campos JRM, Puech-Leao P. Symptoms of anxiety and depression in patients with primary hyperhidrosis and its association with the result of clinical treatment with oxybutynin. Clinics (Sao Paulo). 2021;76:e2892.
5 Weber A, Heger S, Sinkgraven R, Heckmann M, Elsner P, Rzany B. Psychosocial aspects of patients with focal hyperhidrosis. Marked reduction of social phobia, anxiety, and depression and increased quality of life after treatment with botulinum toxin A. Br J Dermatol. 2005;152(2):342-5.
6 de Almeida AR, Montagner S. Botulinum toxin for axillary hyperhidrosis. Dermatol Clin. 2014;32(4):495-504.
7 Wolosker N, de Campos JR, Kauffman P, et al. The use of oxybutynin for treating axillary hyperhidrosis. Ann Vasc Surg. 2011;25(8):1057-62.
8 Wolosker N, Teivelis MP, Krutman M, et al. Long-term results of the use of oxybutynin for the treatment of axillary hyperhidrosis. Ann Vasc Surg. 2014;28(5):1106-12.
9 Du X, Zhu X, Wang T, et al. Compensatory hyperhidrosis after different surgeries at the same sympathetic levels: a meta-analysis. Ann Transl Med. 2018;6(11):203.
10 Nawrocki S, Cha J. Botulinum toxin: Pharmacology and injectable administration for the treatment of primary hyperhidrosis. J Am Acad Dermatol. 2020;82(4):969-79.
11 Wolosker N, Kauffman P, de Campos JRM, et al. Long-term results of the treatment of primary hyperhidrosis with oxybutynin: follow-up of 1,658 cases. Int J Dermatol. 2020;59(6):709-15.
12 Wolosker N, Faustino CB, da Silva MFA, de Campos JRM, Kauffman P. Current treatment options for craniofacial hyperhidrosis. J Vasc Bras. 2020;19:e20190152.
13 Appell RA, Chancellor MB, Zobrist RH, Thomas H, Sanders SW. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc. 2003;78(6):696-702.
14 Abels C, Soeberdt M, Kilic A, et al. A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial. Br J Dermatol. 2021;185(2):315-22.
15 Artzi O, Loizides C, Zur E, Sprecher E. Topical oxybutynin 10% gel for the treatment of primary focal hyperhidrosis: a randomized double-blind placebo-controlled split area study. Acta Derm Venereol. 2017;97(9):1120-4.
16 Nguyen NV, Gralla J, Abbott J, Bruckner AL. Oxybutynin 3% gel for the treatment of primary focal hyperhidrosis in adolescents and young adults. Pediatr Dermatol. 2018;35(2):208-12.
17 Pariser DM, Hebert AA, Drew J, Quiring J, Gopalan R, Glaser DA. Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials. Am J Clin Dermatol. 2019;20(1):135-45.
18 Fujimoto T, Terahara T, Okawa K, Inakura H, Hirayama Y, Yokozeki H. A novel lotion formulation of 20% oxybutynin hydrochloride for the treatment of primary palmar hyperhidrosis: a randomized, placebo-controlled, double-blind, phase III study. J Am Acad Dermatol. 2023;89(1):62-9.
19 Saki N, Shakouri N, Rastaghi F, Hosseini SA, Alipour S, Ahramiyanpour N. Oxybutynin gel versus nanoemulgel for treating primary palmar hyperhidrosis: a pilot double-blind randomized controlled trial. J Cosmet Dermatol. 2023;22(8):2268-72.
20 Nguyen NV, Gralla J, Abbott J, Bruckner AL. Oxybutynin 3% gel for the treatment of primary focal hyperhidrosis in adolescents and young adults. Pediatr Dermatol. 2018;35(2):208-12.
21 Artzi O, Loizides C, Zur E, Sprecher E. Topical oxybutynin 10% gel for the treatment of primary focal hyperhidrosis: a randomized double-blind placebo-controlled split area study. Acta Derm Venereol. 2017;97(9):1120-4.
22 El-Agamy El-Samadony A, Salah Hegab D, Mohamed El Maghraby G, Hamed El-Maadawy I. Topical oxybutynin 3% gel versus aluminum chloride 15% lotion in treatment of primary focal hyperhidrosis. Dermatol Pract Concept. 2023;13(3):e2023192.
23 Milanez De Campos JR, Kauffman P, De Campos Werebe E, et al. Quality of life, before and after thoracic sympathectomy: report on 378 operated patients. Ann Thorac Surg. 2003;76(3):886-91.
24 Varella AYM, Fukuda JM, Teivelis MP, et al. Translation and validation of Hyperhidrosis Disease Severity Scale. Rev Assoc Med Bras. 2016;62(9):843-7.
25 Neves S, Volpiani GG, Paganotti A, et al. Topical oxybutynin deodorant for axillary hyperhidrosis: a topic or a systemic effect? Rationale and design of the phase II today trial. J Vasc Bras. 2025;24:e20240098. PMid:40012967.
26 Cetindag IB, Boley TM, Webb KN, Hazelrigg SR. Long-term results and quality-of-life measures in the management of hyperhidrosis. Thorac Surg Clin. 2008;18(2):217-22.
27 Parashar K, Adlam T, Potts G. The impact of hyperhidrosis on quality of life: a review of the literature. Am J Clin Dermatol. 2023;24(2):187-98.
28 Sakiyama BYP, Monteiro TV, Ishy A, de Campos JRM, Kauffman P, Wolosker N. Quantitative assessment of the intensity of palmar and plantar sweating in patients with primary palmoplantar hyperhidrosis. J Bras Pneumol. 2012;38(5):573-8.
Submitted date:
09/04/2025
Accepted date:
05/26/2026
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email